Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

CEConversations

CEConversations artwork

The New Era of Hemophilia Treatment

Jan 28, 202646 minAudio

We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health, mental health, aging, and everyday habits that protect long‑term outcomes. • Non‑factor prophylaxis versus factor replacement and what each does best • Treating beyond dated trough targets toward durable thrombin generation • Matching therapy to activity level, joint status, and venous access • Why shared decision making beats one‑size‑fits‑all regimens • Practical plans for breakthrough bleeds and procedures • Aging, comorbidities, and proactive screening for liver cancer and heart disease • Weight, movement, physical therapy, and joint load reduction • Vitamin D, bone health, and osteoporosis risk • Chronic pain, anxiety, and skills to break rumination with breathwork • Caregiver choices for kids and the importance of evolving plans This webisode series will provide a review of non-factor prophylaxis therapies for patients with hemophilia A or B with or without inhibitors, as well as provide helpful insights on the roles of gene therapies, considering safety profiles and monitoring requirements, aligning treatment options with lifestyle and individual preferences, and how bleed plans change with the different prophylaxis therapies. These webisodes intend to help patients feel more prepared to engage the hemophilia care team in meaningful conversations that support shared decision-making in treatment planning: https://cmeo.me/PE-020

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Webcast Finding the Right Rhythm: Supporting Pediatric Oncology Nurses in Longitudinal NF1 Management

    Oct 28, 202656 minAudio

    In this CE Concepts recorded symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK...

    Credit the people on this episode

  2. Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1

    Aug 6, 202652 minAudio

    Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in...

    Credit the people on this episode

  3. Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors

    Jul 1, 202632 minAudio

    Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of...

    Credit the people on this episode

  4. Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

    Jul 1, 20261 hr 4 minAudio

    Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform...

    Credit the people on this episode

  5. Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies

    Jul 1, 20261 hr 5 minAudio

    Despite significant advances in the management of advanced or recurrent endometrial cancer (EC) - including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies - delivering timely,...

    Credit the people on this episode